Moderna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.
Follow MRNA
Moderna, Inc. (MRNA) Net income
Moderna, Inc.'s net income for fiscal 2025 was −$2.8B, compared with −$3.6B in fiscal 2024. Over the twelve months to 30 June 2026 it was −$3.2B. Over the past ten years it has ranged from −$4.7B (fiscal 2023) to $12.2B (fiscal 2021); the current reading is higher than 30% of that period. Moderna, Inc. ranks 612th of 612 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$2.8B | — |
| FY2024 | −$3.6B | — |
| FY2023 | −$4.7B | — |
| FY2022 | $8.4B | (31.47%) |
| FY2021 | $12.2B | — |
| FY2020 | −$747.0M | — |
| FY2019 | −$514.0M | — |
| FY2018 | −$384.7M | — |
| FY2017 | −$255.9M | — |
| FY2016 | −$216.2M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$782.0M | — |
| Mar 2026 | −$1.3B | — |
| Dec 2025 | −$826.0M | — |
| Sep 2025 | −$200.0M | — |
| 32 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated compare | $4.4B |
| REGN Regeneron Pharmaceuticals, Inc. compare | $4.3B |
| ARGX argenex SE compare | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $774.7M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $655.7M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| RVMD Revolution Medicines, Inc. compare | −$1.8B |
| MRNA Moderna, Inc. | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on MRNA
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement